Payment overview · 2025
General Payments
$271.37
16 reported records · 11 companies
Healthcare provider profile · identity verified
Richard Ortiz, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1467410290
Verified facts
What the public records show
CMS Open Payments records show Richard Ortiz, MD received $271.37 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.04 | 18.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.26 | 12.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.25 | 11.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.12 | 10.4% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.87 | 8.4% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.73 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.95 | 7.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.52 | 6.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.36 | 6.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $14.14 | 5.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.13 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.37 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 138 |
| Metformin Hcl | Metformin Hcl | 293 | 97 |
| Losartan Potassium | Losartan Potassium | 291 | 80 |
| Lisinopril | Lisinopril | 271 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 59 |
| Simvastatin | Simvastatin | 174 | 53 |
| Glimepiride | Glimepiride | 122 | 40 |
| Omeprazole | Omeprazole | 121 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 51 |
| Metformin Hcl Er | Metformin Hcl | 87 | 25 |
| Ozempic | Semaglutide | 85 | 16 |
| Carvedilol | Carvedilol | 77 | 24 |
| Gabapentin | Gabapentin | 77 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 25 |
| Meloxicam | Meloxicam | 74 | 28 |
| Trazodone Hcl | Trazodone Hcl | 72 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 20 |
| Montelukast Sodium | Montelukast Sodium | 64 | 20 |
| Alendronate Sodium | Alendronate Sodium | 60 | 24 |
| Fenofibrate | Fenofibrate | 60 | 17 |
| Sertraline Hcl | Sertraline Hcl | 60 | 21 |
| Ezetimibe | Ezetimibe | 54 | 16 |
| Tramadol Hcl | Tramadol Hcl | 53 | 22 |
| Buspirone Hcl | Buspirone Hcl | 52 | 18 |
| Furosemide | Furosemide | 51 | 21 |
| Alprazolam | Alprazolam | 48 | 19 |
| Allopurinol | Allopurinol | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Eliquis | Apixaban | 42 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Azithromycin | Azithromycin | 38 | 35 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 31 |
| Pregabalin | Pregabalin | 34 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Famotidine | Famotidine | 32 | 11 |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 13 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 16 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 22 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 13 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.37 · 16 records | Lilly USA, LLC | CRYSVITA, FREESTYLE LIBRE 3, IBSRELA, INJECTAFER, JOURNAVX, KISUNLA, Leqembi, MOUNJARO, OTEZLA, Paradise Ultrasound Renal Denervation System, REPATHA, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error